Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 28, 2016
Pharmacy Choice - Pharmacy News - July 28, 2016

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
7/28/16 - FDA approves lixisenatide as AdlyxinTM for the treatment of adults with type 2 diabetes in the U.S.
Lixisenatide has been approved in the U.S. under the brand name Adlyxin TM indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, including in combination with oral anti-diabetes medication and/or basal insulin. There are an estimated 27.5 million adults with type 2 diabetes in the U.S., and the U.S market co
7/28/16 - FDA Approves Sanofi's Adlyxin For Treatment Of Adults With Type 2 Diabetes
PARIS- Sanofi said that the U.S. Food and Drug Administration approved Adlyxin or lixisenatide, a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. Commercial launches include most EU countries, Japan, Brazil, Mexico and India. The approval of Adlyxin
7/28/16 - Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
--Sanofi announced today that the U.S. Food and Drug Administration approved Adlyxin TM, a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. "The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people livin
7/28/16 - Special Notice - Development of an approved Food and Drug Administration (FDA) TBI Assay Cartridge for the i-STAT- , using UCHL1 and GFAP protein biomarkers
Special Notice- Development of an approved Food and Drug Administration TBI Assay Cartridge for the i-STAT-, using UCHL1 and GFAP protein biomarkers. Office Address: Department of the Army; U.S. Army Medical Research Acquisition Activity; Attn: MCMR-AAA820 Chandler Street Frederick, MD 21702-5014 MD 21702-5014. Subject: Development of an approved F
7/27/16 - 4WEB Medical Announces FDA Clearance of Lateral Spine Truss System
--4 WEB Medical, the industry leader in 3 D printed orthopedic implants, announced today that the company has received 510 K clearance from the FDA for its lateral interbody fusion device. "The Lateral Spine Truss System represents a significant advancement in treatment options for lateral spine surgery," said Frank Cammisa, MD, Professor and Chie
7/27/16 - AbbVie receives FDA approval for new Hepatitis C drug
US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C...

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415